Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial

The ITACa trial was designed to define the role of cetuximab (Cet) and bevacizumab (Bev) in combination with standard chemotherapy (CT, FOLFIRI or FOLFOX4) as first- and second-line treatment in metastatic colorectal cancer. All patients with WT KRAS tumors who had been enrolled in the first-line tr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Passardi, Alessandro, Scarpi, Emanuela, Gelsomino, Fabio, Palladino, Maria Angela, Casadei Gardini, Andrea, Turci, Daniele, Chiuri, Vincenzo Emanuele, Mucciarini, Claudia, Tassinari, Davide, Ragazzini, Angela, Frassineti, Giovanni Luca, Valgiusti, Martina, Ulivi, Paola, Amadori, Dino
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5585399/
https://ncbi.nlm.nih.gov/pubmed/28874797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-11048-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires